A randomized phase III study to compare conventional chemotherapy (CHOEP-14) + rituximab vs high-dose chemotherapy followed by autologous stem cell transplantation (Mega-CHOEP-21) + rituximab in younger patients with aggressive NHL

Trial Profile

A randomized phase III study to compare conventional chemotherapy (CHOEP-14) + rituximab vs high-dose chemotherapy followed by autologous stem cell transplantation (Mega-CHOEP-21) + rituximab in younger patients with aggressive NHL

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Vincristine
  • Indications B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms R-MegaCHOEP
  • Most Recent Events

    • 01 Aug 2017 Results of pooled data of clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within two prospective clinical trials (RICOVER-60 and R-MegaCHOEP) of the German high-grade non-Hodgkin's lymphoma study group were, published in the Journal of Clinical Oncology.
    • 06 Dec 2016 Results of retrospective analysis from this and other study presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 15 Nov 2012 Results published in the Lancet Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top